Product
Pembrolizumab + Lenvatinib
3 clinical trials
3 indications
Indication
Advanced Renal Cell CarcinomaIndication
Adrenocortical CancerIndication
Biliary Tract NeoplasmsClinical trial
Real-World Treatment Patterns and Outcomes of Advanced Renal Cell Carcinoma (aRCC) Patients Receiving Nivolumab+Ipilimumab or Pembrolizumab+Lenvatinib in U.S. Oncology PracticeStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based ChemotherapyStatus: , Estimated PCD: 2025-08-31
Clinical trial
A Phase II, Multicenter, Randomized Study of Pembrolizumab With or Without Chemotherapy or Lenvatinib in First-Line Treatment of Advanced Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2024-12-31